BLOOMFIELD HILLS, Mich. / Oct 30, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO... Read More